{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:31:13Z","timestamp":1780579873356,"version":"3.54.1"},"reference-count":37,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2022,8,3]]},"DOI":"10.1080\/14737140.2022.2102482","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T22:23:43Z","timestamp":1657837423000},"page":"815-822","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Nivolumab plus ipilimumab in malignant pleural mesothelioma"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6904-6507","authenticated-orcid":false,"given":"Camille","family":"Travert","sequence":"first","affiliation":[{"name":"Institut du Cancer de Montpellier","place":["Montpellier, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Tomasini","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, APHM, INSERM, CNRS, CRCM, H\u00f4pital Nord","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, APHM, INSERM, CNRS, CRCM, H\u00f4pital Nord","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"WHO. Global mesothelioma deaths reported to the world health organization between 1994 and 2008 [Internet]. WHO. World Health Organization; [cited 2021 Feb 16]. Available from: https:\/\/www.who.int\/bulletin\/volumes\/89\/10\/11-086678\/en\/"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0087"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00000811"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32931"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.038"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0103"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30765-4"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8"},{"issue":"11","key":"e_1_3_5_13_1","first-page":"502","article-title":"FDA approves nivolumab plus ipilimumab for previously untreated unresectable malignant pleural mesothelioma","volume":"34","author":"Wright K.","year":"2020","unstructured":"Wright K. FDA approves nivolumab plus ipilimumab for previously untreated unresectable malignant pleural mesothelioma. Oncology (Williston Park). 2020 12;34(11):502\u20133.","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30151-6"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30462-9"},{"key":"e_1_3_5_16_1","unstructured":"European Thoracic Oncology Platform. A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as First-line treatment for advanced malignant pleural mesothelioma [Internet]. clinicaltrials.gov; 2021 Feb [cit\u00e9 2021 Feb 15]. Report No.: NCT03762018. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03762018"},{"key":"e_1_3_5_17_1","unstructured":"Canadian Cancer Trials Group. A phase II\/III randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma [Internet]. clinicaltrials.gov; 2021 Jan [cit\u00e9 2021 Feb 15]. Report No.: NCT02784171. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02784171"},{"key":"e_1_3_5_18_1","unstructured":"opdivo-epar-public-assessment-report_en.pdf [Internet]. [cited 2021 Feb 16]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/opdivo-epar-public-assessment-report_en.pdf"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1175694"},{"key":"e_1_3_5_20_1","unstructured":"yervoy-epar-product-information_en.pdf [Internet]. [cited 2021 Feb 16]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yervoy-epar-product-information_en.pdf"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1927"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30169-9"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5428"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30446-1"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.007"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30515-4"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-19-686"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30420-X"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.009"},{"key":"e_1_3_5_33_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology [Internet]. [cited 16 f\u00e9vr 2021]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231"},{"key":"e_1_3_5_35_1","unstructured":"European medicines agency validates Bristol Myers squibb\u2019s type II variation application for opdivo (nivolumab) plus Yervoy (ipilimumab) for First-line Treatment of malignant pleural mesothelioma [Internet]. [cited 2021 Feb 16]. Available from: https:\/\/news.bms.com\/news\/corporate-financial\/2020\/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Type-II-Variation-Application-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-for-First-line-Treatment-of-Malignant-Pleural-Mesothelioma\/default.aspx"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121071"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000177"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0613-x"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2022.2102482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:39:23Z","timestamp":1770291563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2022.2102482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,3]]}},"alternative-id":["10.1080\/14737140.2022.2102482"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2022.2102482","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-03-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}